文献速递临床试验与 GCP流行病学与生物统计

胃旁路术联合生活方式干预对糖尿病5年控制目标的影响

Lifestyle Intervention and Medical Management With vs Without Roux-en-Y Gastric Bypass and Control of Hemoglobin A1c, LDL Cholesterol, and Systolic Blood Pressure at 5 Years in the Diabetes Surgery Study.
PubMed 文献 · JAMA · 2018-01-01

该研究为一项随机临床试验的观察性随访,纳入120例HbA1c≥8.0%、BMI 30.0-39.9的成人2型糖尿病患者,比较在强化生活方式与医疗管理基础上加用Roux-en-Y胃旁路术与否对5年糖尿病控制目标的影响。5年时手术组达到复合终点者23% vs 生活方式-医疗管理组4%(差值19%,95%CI 4%-34%,P=.01),HbA1c<7.0%者55% vs 14%(差值41%,95%CI 19%-63%,P=.002),但手术组严重不良事件更多(66 vs 38),且效应量在5年间减弱。

要点

  • 5年时手术组复合终点达标23% vs 对照组4%,差异有统计学意义。
  • 第5年HbA1c<7.0%者手术组55% vs 对照组14%。
  • 手术组严重不良事件66起 vs 对照组38起,多为胃肠道及手术并发症。

核心结论

  • 在肥胖2型糖尿病成人中,与单纯生活方式和强化医疗管理相比,加用胃旁路术在5年时复合终点仍显著更优,但效应量随5年随访减弱,需进一步随访了解改善的持久性。

研究设计与样本

  • 随机临床试验的观察性随访,美国与台湾4个中心,120例HbA1c≥8.0%且BMI 30.0-39.9的参与者(2008年4月至2011年12月入组),随访5年至2016年11月。
  • 干预为基于Diabetes Prevention Program和LookAHEAD试验的2年强化生活方式与医疗管理,加或不加Roux-en-Y胃旁路术(每组60例),随后观察至第5年。
  • 120例中98例(82%)完成5年随访;平均年龄49岁(SD 8岁),女性72例(60%)。

主要发现

  • 5年时手术组13例(23%)vs 生活方式-医疗管理组2例(4%)达到复合终点(差值19%,95%CI 4%-34%,P=.01)。
  • 第5年手术组31例(55%)vs 生活方式-医疗管理组8例(14%)HbA1c<7.0%(差值41%,95%CI 19%-63%,P=.002)。
  • 手术组严重不良事件66起 vs 生活方式-医疗管理组38起,最常见为胃肠道事件及狭窄、小肠梗阻、漏等手术并发症。
  • 手术组甲状旁腺激素升高更多,但B12缺乏无差异。
  • 基线BMI均值(SD)生活方式-医疗管理组34.4(3.2)、胃旁路组34.9(3.0);HbA1c分别为9.6%(1.2)和9.6%(1.0)。

关键数值与推荐

  • 复合三重终点采用美国糖尿病协会标准:HbA1c<7.0%、LDL胆固醇<100 mg/dL、收缩压<130 mm Hg。
  • 干预方案基于Diabetes Prevention Program和LookAHEAD试验的强化生活方式与医疗管理,持续2年。

临床怎么用

  • 对肥胖2型糖尿病成人,在强化生活方式与医疗管理基础上加用胃旁路术可能有助于5年时达到HbA1c、LDL胆固醇和收缩压复合目标,但需权衡其更多的严重不良事件。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The Roux-en-Y gastric bypass is effective in achieving established diabetes treatment targets, but durability is unknown. OBJECTIVE: To compare durability of Roux-en-Y gastric bypass added to intensive lifestyle and medical management in achieving diabetes control targets. DESIGN, SETTING, AND PARTICIPANTS: Observational follow-up of a randomized clinical trial at 4 sites in the United States and Taiwan, involving 120 participants who had a hemoglobin A1c (HbA1c) level of 8.0% or higher and a body mass index between 30.0 and 39.9 (enrolled between April 2008 and December 2011) were followed up for 5 years, ending in November 2016. INTERVENTIONS: Lifestyle-intensive medical management intervention based on the Diabetes Prevention Program and LookAHEAD trials for 2 years, with and without (60 participants each) Roux-en-Y gastric bypass surgery followed by observation to year 5. MAIN OUTCOMES AND MEASURES: The American Diabetes Association composite triple end point of hemoglobin A1c less than 7.0%, low-density lipoprotein cholesterol less than 100 mg/dL, and systolic blood pressure less than 130 mm Hg at 5 years. RESULTS: Of 120 participants who were initially randomized (mean age, 49 years [SD, 8 years], 72 women [60%]), 98 (82%) completed 5 years of follow-up. Baseline characteristics were similar between groups: mean (SD) body mass index 34.4 (3.2) for the lifestyle-medical management group and 34.9 (3.0) for the gastric bypass group and had hemoglobin A1c levels of 9.6% (1.2) and 9.6% (1.0), respectively. At 5 years, 13 participants (23%) in the gastric bypass group and 2 (4%) in the lifestyle-intensive medical management group had achieved the composite triple end point (difference, 19%; 95% CI, 4%-34%; P = .01). In the fifth year, 31 patients (55%) in the gastric bypass group vs 8 (14%) in the lifestyle-medical management group achieved an HbA1c level of less than 7.0% (difference, 41%; 95% CI, 19%-63%; P = .002). Gastric bypass had more serious adverse events than did the lifestyle-medical management intervention, 66 events vs 38 events, most frequently gastrointestinal events and surgical complications such as strictures, small bowel obstructions, and leaks. Gastric bypass had more parathyroid hormone elevation but no difference in B12 deficiency. CONCLUSIONS AND RELEVANCE: In extended follow-up of obese adults with type 2 diabetes randomized to adding gastric bypass compared with lifestyle and intensive medical management alone, there remained a significantly better composite triple end point in the surgical group at 5 years. However, because the effect size diminished over 5 years, further follow-up is needed to understand the durability of the improvement. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00641251.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Ikramuddin S, Korner J, Lee WJ, et al. Lifestyle Intervention and Medical Management With vs Without Roux-en-Y Gastric Bypass and Control of Hemoglobin A1c, LDL Cholesterol, and Systolic Blood Pressure at 5 Years in the Diabetes Surgery Study. JAMA. 2018. PMID: 29340678. doi:10.1001/jama.2017.20813

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。